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Introduction
Fungal infections are being increasingly diagnosed in 
patients admitted to the intensive care unit (ICU). 
Advances in medical science allow patients with severe 
and complicated diseases to survive, and thus a 
population of subjects vulnerable to a range of infections 
is created. Candida is the most common fungal pathogen 
in ICU patients, and the main clinical forms are blood-
stream infection, followed by peritonitis and other 
abdominal infection, endocarditis, and so forth. Most of 
the patients included in studies on epidemiology or treat-
ment of invasive candidiasis had candidemia (approxi-
mately 68 to 90%), with or without other sites aﬀ  ected, 
while peritonitis was the second most common disease 
(approximately 7 to 30% of subjects) [1-3].
Candidemia is a life-threatening infection with high 
morbidity and mortality, especially in immunocom  pro-
mised and critically ill patients [4-7]. In the ICU, this 
infection may represent up to 15% of nosocomial infec-
tions and the crude mortality rate has been found as high 
as 25 to 60%, varying according to the study design and 
the population – with the estimated attributable 
mortality as high as 47% [8-11]. Additionally, the 
estimated costs of each episode of invasive candidiasis in 
hospitalised adults are tremendous [11,12]. Finally, noso-
comial fungal infections have one of the highest rates of 
inappropriate therapy – consisting mostly of omission of 
initial empirical therapy and an inadequate dose of 
ﬂ  uconazole – which has been associated with increased 
mortality [13-16].
Moreover, during the past decade, several new anti-
fungal drugs have been developed and obtained approval 
for treatment of Candida infections. Among them, 
echinocandins are the most important from the point of 
view of treating candidemia in critically ill patients. 
Epidemiology, risk factors, diagnosis and, in particular, 
treatment strategies and guidelines will therefore be 
discussed further.
Epidemiology of invasive candidiasis
Candidemia is one of the most frequent and most serious 
infections in patients admitted to the ICU, being the 
fourth most frequent pathogen of bloodstream infections 
in North America [17]. Moreover, candidemia in the ICU 
is by far more common than in most other wards and can 
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Additionally, Candida species account for approximately 
3% of all surgery-related peritoneal infections, both 
community-acquired infections and nosocomial infections 
[20]. A recent French study on invasive candidiasis in the 
ICU revealed that approximately one-third of patients 
presented each of the clinical forms: isolated candidemia, 
invasive candidiasis with candidemia and invasive 
candidiasis only [1].
Th  e epidemiology of Candida infections – both on a 
worldwide scale and, more importantly, on a local level – 
has signiﬁ   cant implications for management of this 
infection. In particular, given the well-known, albeit not 
universal, diﬀ  erences in antifungal susceptibility among 
diﬀ  erent Candida species, the choice of the most appro-
priate empirical treatment can be successfully based on 
epidemiological data regarding the frequency of Candida 
parapsilosis and ﬂ  uconazole-resistant species in a given 
centre.
During the past two decades, most hospitals have 
reported a progressive shift in the species of Candida. In 
the past, almost all isolates responsible for bloodstream 
infections were Candida albicans, whereas in recent 
years a growing proportion of episodes of candidemia 
have been caused by Candida species other than 
C. albicans [21-25]. Even though, C. albicans remains the 
predominant strain in most countries [26,27], even 
among critically ill patients [1,7,21,28,29], non-albicans 
species are increasingly common – some ICUs have 
reported recently that non-albicans species are respon-
sible for over 50% of candidemia episodes in adult 
critically ill patients [24,30]. Th  e most common non-
albicans species are C. parapsilosis or Candida glabrata, 
followed by Candida tropicalis and Candida krusei 
[1,24,31-33]. Rare Candida species reported to cause 
candidemia include Candida lusitaniae,  Candida 
guilliermondii and Candida rugosa [15,31].
Numerous studies have tried to ﬁ  nd reasons for this 
shift, and several risk factors have been associated with 
candidemia due to diﬀ  erent species [25,34]. It is under-
standable that the widespread use of ﬂ  uconazole  can 
predispose patients to the development of infections due 
to species that are resistant to azoles, either intrinsically 
fully resistant such as C. krusei or in dose-dependent 
fashion such as C. glabrata. Indeed, previous use of 
ﬂ  uconazole has been found to be a risk factor for the 
presence of non-albicans  fungaemia [24,25,35] even 
though some studies did not ﬁ  nd this association [23]. 
Speciﬁ  c risk factors for candidemia due to other non-
albicans strains have also been reported, such as for 
example the presence of in-dwelling devices, hyper-
alimentation and being a neonate for C. parapsilosis [31]. 
Th  e  speciﬁ   c risk factors associated with diﬀ  erent 
Candida species are outlined in Table 1.
Even though the overall rise in incidence of non-
albicans strains is alarming, from the clinical point of 
view there are important diﬀ  erences among the diﬀ  erent 
species. Speciﬁ   cally, the main diﬀ  erence  between 
C. albicans and C. kusei or C. glabrata is the resistance to 
the most frequently used antifungal (that is, ﬂ  uconazole). 
Th  e  diﬀ  erences in susceptibility to various antifungals are 
partially predictable and are reported in Table 2. Species 
identiﬁ  cation and knowledge of the local epidemiology of 
Candida strains causing candidemia are therefore of the 
utmost importance for guiding appropriate empirical 
therapy. On the contrary, in vitro susceptibility testing of 
clinical isolates of Candida proves extremely valuable for 
guiding therapy in patients who have received prior 
antifungal treatment or who are not responding to 
empirical therapy.
Risk factors for invasive candidiasis in the ICU and 
predictive scores
Although invasive Candida infections can aﬀ  ect  any 
hospitalised patient, they are more common and have 
unique attributes in certain populations, including 
patients with cancer, haematological malignancy or other 
immunosuppression. Th   e predominant source of invasive 
Candida infection is endogenous, from superﬁ  cial 
mucosal and cutaneous proliferation to haematogenous 
dissemination [36]. Rare cases of exogenous transmission 
have been described due to contaminated solutions and 
materials or transmission from healthcare workers to 
patients and from patients to patients [37,38].
Th  e suppression of the normal bacterial ﬂ  ora in the 
gastrointestinal tract by broad-spectrum antibiotic 
Table 1. Particular risk factors associated with candidemia 
due to diff  erent Candida species
Candida species  Risk factor
Candida tropicalis  Neutropenia and bone marrow transplantation
Candida krusei Fluconazole  use
  Neutropenia and bone marrow transplantation
Candida glabrata Fluconazole  use
 Surgery
 Vascular  catheters
 Cancer
 Older  age
Candida parapsilosis  Parenteral nutrition and hyperalimentation
 Vascular  catheters
 Being  neonatea
Candida lusitaniae and   Previous polyene use
Candida guilliermondii
Candida rugosa Burns
Adapted from [6,31,70,71]. aEpidemics due to nosocomial horizontal 
transmission via hands of health personnel have been reported [72,73].
Bassetti et al. Critical Care 2010, 14:244 
http://ccforum.com/content/14/6/244
Page 2 of 12therapy also allows the yeast to proliferate, both in 
neutro  penic patients with haematological malignancies 
[39] and in non-neutropenic patients [40], and long-term 
and high-density colonisation has been shown to lead to 
candidemia. Numerous conditions frequent in ICU 
patients – such as parenteral nutrition, intravascular 
catheters, trauma, hypotension, therapy with steroids or 
cyclosporine, and ischaemia and reperfusion – may 
damage the integrity of skin or the gastrointestinal 
mucosa with penetration by the yeast, potentially leading 
to systemic infection. Th   e factors predisposing critically 
ill patients to candidemia are presented in Table 3, with 
the presence of vascular catheters or disruption of the 
gut or skin barrier among the most important.
Important eﬀ  orts are focused on identifying critically 
ill patients at high risk of developing candidemia in order 
to apply the most eﬃ   cacious management strategy and 
avoid high mortality. Risk prediction scores have thus 
been developed and diﬀ  erent parameters combined to 
predict which patients would develop candidiasis. In par-
ti  cular, the score by Leon and colleagues included 
parenteral nutrition (1 point), surgery (1 point), multi-
focal colonisation (1 point), and severe sepsis (2 points); 
subjects with score >2.5 were almost eight times more 
likely to develop candidiasis than those with score <2.5 
[41]. Th   e other score by Ostrosky-Zeichner and 
colleagues found that the combination of the systemic 
antibiotic treatment or central venous catheter and two 
or more of ﬁ   ve other variables (parenteral nutrition, 
dialysis, major surgery, pancreatitis, treatment with 
steroids or other immuno  suppressive agents) had, in 
their population, positive and negative predictive values 
of 10% and 97%, respectively [42]. Additionally, Dupont 
and colleagues published in 2003 a predictive score for 
peritoneum Candida infection in the ICU: the presence 
of three out of four factors (female gender, upper 
gastrointestinal tract origin of peritonitis, intra  operative 
cardiovascular failure and previous antibiotic therapy) 
had positive and negative predictive values of 67% and 
72%, respectively [43].
Th   anks to such scores speciﬁ  cally developed and then 
validated in ICU patients, the risk of invasive candidiasis 
can be estimated because the presence of the above-
mentioned risk factors is directly related to the 
percentage probability of developing invasive candidiasis, 
allowing one to judge whether risk of candidemia 
warrants any therapeutic measures.
Diagnosis of candidemia
Blood cultures remain the mainstay for diagnosing candi-
demia, but the sensitivity reported frequently is not 
optimal. Moreover, the time from blood sample collec-
tion and the microbiological response of growing yeast is 
often lengthy. Furthermore, several more days are 
required for species identiﬁ   cation and susceptibility 
testing. New methods for diagnosis of invasive Candida 
infection have therefore been investigated, including 
Table 2. Common susceptibility of various Candida species
Species Amphotericin  B  Echinocandinsa  Fluconazole Itraconazole  Voriconazoleb
Candida albicans  S  S  S to Rc S  S
Candida glabrata  S  S  S-DD to R  S-DD to R  S to Rd
Candida krusei  S  S  R  S-DD to R  S
Candida lusitaniae  S to Re  S S  S S
Candida parapsilosis  S  S to Rf S  S  S
Candida tropicalis  S S  S S  S
Adapted from [1,44,67,74,75]. S, susceptible; S-DD, susceptible dose-dependent; R, resistant. aSusceptibility pattern is similar for all the echinocandins available 
(anidulafungin, caspofungin and micafungin). bPosaconazole has the same susceptibility pattern as voriconazole but, lacking intravenous formulation, has little place 
in the treatment of candidemia in the intensive care unit. cResistant in approximately 5%. dCross-resistance to azoles in more than 5%.eResistance uncommon but can 
develop in initially susceptible species. fHigher minimum inhibitory concentration values and poor activity against C. parapsilosis biofi  lm.
Table 3. Factors predisposing intensive care unit patients 
to candidemia
Population Risk  factors
All patients  Prior abdominal surgery
 Intravascular  catheters
 Parenteral  nutrition
  Use of broad-spectrum antibiotics
  Immunosuppression, including corticosteroid 
 therapy 
  Acute renal failure
 Diabetes
 Transplantation
 Haemodialysis
 Pancreatitis
Specifi  c for ICU patients  Prolonged stay in the ICU
  Candida colonisation, particularly if multifocal
  High Acute Physiology and Chronic Health 
  Evaluation II score
  Low birth weight for neonatal ICU
Adapted from [4,6,76]. ICU, intensive care unit.
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time PCR; however, only the use of β-d-glucan has been 
included in the 2008 Infectious Diseases Society of 
America guidelines for diagnosing invasive fungal disease 
[44].
Th   e use of β-d-glucan is currently being investigated in 
ICU populations. Even though the results seem 
promising, no large prospective studies have been 
performed and the main problems for the use of β-d-
glucan remain its high cost and high rate of false positive 
results (mostly due to concomitant bacterial bloodstream 
infections and intensive care measures such as haemo  ﬁ  l-
tration, albumin or immunoglobulin use) [45]. Traditional 
culture from sterile sites other than the bloodstream (for 
example, the peritoneum) are useful for diagnosis of 
invasive candidiasis. For speciﬁ  c details on the diagnosis 
of invasive candidiasis in the ICU, a recent review is 
available [46].
Management of candidemia in the ICU
As far as management of candidemia in the ICU is 
concerned, there is no single strategy that can be 
considered the most appropriate. In fact, diﬀ  erent 
approaches can be chosen and can be judged as the best 
for a given clinical situation. In particular, four manage-
ment options are available: prophylaxis, empirical 
therapy, pre-emptive therapy and treatment of a culture-
proven infection. So how is the best strategy chosen?
Th  e knowledge of epidemiological data, the above-
mentioned risk factors and, ﬁ  rst of all, the analysis of 
local epidemiology of candidemia in a singular ICU allow 
one to determine whether a patient is at low, modest or 
high risk of developing this infection. Consequently, a 
choice between the most appropriate management 
strategies can be made – the patients with low or modest 
risk of infection can be monitored less frequently for 
Candida colonisation, while high-risk subjects may 
beneﬁ  t from immediate diagnostic procedures (cultures 
of both sterile and nonsterile sites, testing for serological 
markers) and empirical antifungal therapy. In the case of 
negative results of testing for yeasts, antifungal 
prophylaxis might be considered. Naturally, knowing the 
most frequent species and susceptibility patterns of 
Candida isolated in a single ICU is the basis for choosing 
an adequate antifungal agent (Table 4).
Prophylaxis in the ICU
Prophylaxis – deﬁ  ned as administration of an antifungal 
agent to a patient with no evidence of infection – has 
been evaluated in several studies and meta-analyses 
[27,47-50], and its main advantage is a possible reduction 
in the rate of candidemia.
Since morbidity and mortality rates in patients with 
systemic fungal infections are exceedingly high, the use 
of an eﬀ  ective antifungal prophylaxis in selected high-
risk patients is very attractive and might be an option in 
this select population. Th   e strategy of antifungal prophy-
laxis is now well established in patients with persistent 
neutropenia after treatment for haematological malig-
nan  cies or after bone marrow transplantation, but 
routine use of antifungal prophylaxis in the general ICU 
setting is discouraged [51-53]. Nonetheless, the 
implementation of targeted anti  fungal prophylaxis has 
been shown to be eﬀ  ective in certain ICU settings [27,47], 
and three randomised placebo-controlled trails reported 
a clear >50% decrease in the incidence of Candida 
infections with ﬂ  uconazole prophylaxis [54-56]. More-
over, two meta-analyses con  ﬁ   rmed that prophylactic 
ﬂ  uconazole administration in ICU patients reduced the 
rate of Candida infection, but no clear survival advantage 
was observed [49,50]. In the meta-analysis by Playford 
and colleagues, however, only when the studies on 
prophylaxis with both ﬂ  uconazole and ketonazole were 
considered was the total mortality found reduced by 
approximately 25% and the incidence of fungal infection 
by 50% [50]. Th   e meta-analysis by Cruciani and 
colleagues also reported, along with a relative risk 
reduction in candidemia, a decrease in overall mortality 
with antifungal prophylaxis with various agents [48].
On the other hand, the disadvantages of ﬂ  uconazole 
prophylaxis include possible toxicity and profound 
inﬂ  uence on local epidemiology with the emergence of 
ﬂ  uconazole-resistant isolates [57]. From expert opinion 
expressed in reviews and guidelines [44,58], therefore, 
antifungal prophylaxis might be warranted only for ICUs 
with a high rate of invasive candidiasis, as compared with 
the normal rates of 1 to 2%, particularly for selected 
patients who are at highest risk (>10%) [42]. Th  e  approach 
of limiting prophylaxis to a subgroup of patients with the 
highest risk of candidemia may help to limit the quantity 
of antifungals used and delay the emergence of infections 
due to ﬂ  uconazole-resistant Candida strains seen in 
immunocompromised patients. In fact, this approach is 
supported by the recent Infectious Diseases Society of 
America guidelines that recommend ﬂ  uconazole prophy-
laxis at a dose of 400 mg (6 mg/kg) daily for high-risk adult 
patients hospitalised in ICUs that have a high incidence of 
invasive candidiasis [44].
Empirical therapy
Empirical treatment is deﬁ   ned as administration of 
antifungals in the presence of persistent and refractory 
fever in patients who are at high risk for fungal infection. 
Th   is strategy was developed almost three decades ago for 
neutropenic patients, when it became evident that the 
lack of sensitivity of microbiological and clinical ﬁ  ndings 
resulted in delayed diagnosis and increased morbidity 
and mortality.
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underpowered, the treatment being used in diﬀ  erent 
clinical settings and numerous antifungals are being 
registered and recommended for empirical treatment of 
invasive candidiasis, both in neutropenic patients and in 
non-neutropenic patients [44]. All these eﬀ  orts are aimed 
at reducing morbidity and mortality by starting treatment 
as early as possible, given the evidence that a delay in 
antifungal prescription increases mortality rates signiﬁ  -
cantly in candidemia [13,14]. In the ICU, however, where 
numer  ous patients have diﬀ  erent risk factors for fungal 
infections, the routine use of empirical therapy in cases 
of persistent fever may result in signiﬁ  cant overtreatment. 
Th   e strategy of a pre-emptive approach therefore appears 
promising. In fact, US guidelines recommend that such 
an approach (although they continue to call it empirical 
treatment) should be considered for critically ill patients 
with risk factors for invasive candidiasis and no other 
known cause of fever, based on clinical assessment of risk 
factors, serologic markers for invasive candidiasis and/or 
culture data from nonsterile sites [44] (Table 4).
Pre-emptive therapy
Th   e main concept of a pre-emptive strategy is to better 
identify patients at high risk for developing candidemia. 
Th   e overall use of antifungals in the ICU can therefore be 
reduced, without delaying therapy in patients who need 
it. Th  e recent availability of more sensitive and speciﬁ  c 
clinical and laboratory tools allows for better 
identiﬁ  cation of high-risk patients, and this approach has 
been used success  fully [59]. Th   e question arises, however, 
of how to deﬁ  ne a patient at high risk for developing 
candidemia. No clear predictive rule exists, but the two 
score systems described above for ICU patients can be of 
some help. In brief, multifocal colonisation by Candida 
and/or the presence of well-described factors outlined in 
Table 3 make the patient a suitable candidate for 
empirical therapy if any signs or symptoms of infection 
compare.
In particular, the eﬃ   cacy of a pre-emptive strategy in 
ICU patients has been recently established in a single-
institution study in which the use of ﬂ  uconazole  in 
patients with corrected colonisation index ≥0.5, 
des  cribed previously by Pittet and colleagues [40], has 
signiﬁ  cantly decreased the incidence of invasive candi-
diasis [60]. More  over, surrogate markers of invasive 
fungal infections have been studied extensively. In 
particular, β-d-glucan is a component of the cell wall of 
Candida and other fungi and has been investigated as a 
serological marker for fungal infections, including 
candidemia [61]. Even though false positive results have 
been reported and its routine use in the ICU requires 
further validation, persistently high serum levels of β-d-
glucan in ICU patients were found indicative of fungal 
disease [45].
A pre-emptive approach in critically ill patients might 
therefore be deﬁ   ned as starting antifungals when the 
following conditions are satisﬁ  ed: the presence of long 
ICU stay (>96 hours), and broad-spectrum antibiotic 
therapy; the presence of any other risk factors, such as 
severe sepsis, gastrointestinal surgery or parenteral 
nutrition; plus microbiological evidence of Candida 
infection, including multifocal colonisation or a positive 
result for serum β-d-glucan. Th  e proposed approach is 
shown in Figure  1 and, as with any new strategy, will 
warrant valida  tion in prospective trails. One of the main 
advantages of such an approach is limiting the use of 
antifungals in low-risk patients, while starting treatment 
for candidemia without delay when symptoms appear in 
patients at high risk for this infection. Th  e  beneﬁ  t of early 
therapy, in terms of morbidity and mortality, can thus be 
obtained, while overtreatment can be avoided (Figure 2).
Treatment of a culture-documented candidemia
For ICU patients with low/medium risk of developing 
candidemia, blood cultures should be performed if a 
clinical suspicion of systemic infection is present, even in 
the absence of fever. Numerous blood cultures, both 
from a central venous catheter and a peripheral line, 
remain the cornerstone for diagnosis of candidemia. As 
any delay before administering primary therapy can lead 
to a noticeable increase in mortality, antifungals should 
be prescribed as soon as there is growth of yeasts in 
blood samples.
Th  e choice of antifungal for an unknown Candida 
species should be based on the knowledge of local 
Table 4. Choice of antifungals for treatment of candidemia in critically ill patients
Treatment First  choice  Alternative
Pre-emptive or empirical  Echinocandin  Lipid formulation of amphotericin B
Culture-proven candidemia   
 C andida albicans  Echinocandin  Fluconazole or lipid formulation of amphotericin B
 Candida  glabrata  Echinocandin  Lipid formulation of amphotericin B
 Candida  krusei  Echinocandin  Lipid formulation of amphotericin B
 Candida  parapsilosis  Lipid formulation of amphotericin B  Echinocandin or fl  uconazole
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to C. albicans and where ﬂ  uconazole resistance is low, 
ﬂ  uconazole is the drug of choice. On the other hand, in 
an ICU where ﬂ  uconazole-resistant species are common 
(for example, C. glabrata) or in patients colonised with 
ﬂ  uconazole-resistant strains, echinocandins are the drugs 
of choice. Moreover, for patients in severe or moderately 
severe clinical conditions (for example, haemody-
namically unstable patients, with suspected concomitant 
endocardial involvement), echinocandins are recom-
mended because of their bactericidal activity against 
Candida; the side eﬀ  ects are less common than those 
reported for the other fungicidal agent – liposomal 
ampho  tericin B [44]. Th   e antifungal treatment might be 
modiﬁ  ed according to the results of susceptibility testing, 
and de-escalation to ﬂ  uconazole has been successful for 
stable patients with susceptible isolates [44].
Other aspects of treating candidemia in the ICU
Once the initial therapy for candidemia is started, several 
clinical issues remain open. Firstly, the eﬃ   cacy of the 
treatment should be assessed by the documentation of 
blood cultures returning sterile. Moreover, the date of the 
ﬁ   rst negative blood culture is important, because the 
recommended length of treatment is 14 days after the 
documented clearance of Candida from the bloodstream 
and resolution of symptoms attributable to candidemia.
Secondly, the antifungal chosen empirically can be 
changed based on the results of species determination or 
susceptibility testing. For stable patients with C. albicans 
or other ﬂ   uconazole-susceptible strains, ﬂ  uconazole  is 
therefore the drug of choice. Importantly, ﬂ  uconazole is 
the preferred treatment for C. parapsilosis, since resis-
tance to echinocandins has been reported [62].
Th  irdly, patients who improved clinically and who 
cleared Candida from the bloodstream might be suitable 
for step-down oral therapy to complete the course of 
14  days. Th  e available oral antifungals are ﬂ  uconazole, 
itraconazole, voriconazole and posaconazole. Fluconazole 
is an obvious choice for susceptible species, while 
voriconazole can be indicated as step-down therapy for 
C. krusei or voriconazole-susceptible C. glabrata.
Additionally, ophthalmologic fundus examination is 
warranted in all the patients to exclude disseminated 
endocular infection, and endocarditis should be excluded 
in case of persistently positive blood cultures, known 
valve pathology or any other sign or symptom suggestive 
of endocardial involvement. In both cases, the duration 
of treatment is much longer (>4 weeks and up to lifelong 
suppressive therapy) and is described in detail elsewhere 
[44].
Last but not least, intravenous catheter removal is 
strongly recommended for patients with candidemia. 
Guidelines both on management of candidiasis and on 
management of catheter-related bloodstream infection 
state clearly that catheters should be removed, even 
though grade II and grade III of such statements indicate 
that there are no data from properly randomised, con-
trolled trials [44,63,64]. Interestingly, a recent study of 
842 adults included in candidemia trials did not ﬁ  nd on 
multivariate analysis any beneﬁ   t from early catheter 
removal; the expert guidelines remain the best synthesis 
of all available data, however, and removing the catheter 
should thus be attempted in all ICU patients with 
candidemia [64].
Bioﬁ  lm production is a well-documented phenomenon 
for  Candida  species that signiﬁ   cantly contributes to 
Candida  pathogenicity in catheter-related bloodstream 
infections, resulting in recurrent or persistent infections 
and bioﬁ   lm-mediated antifungal resistance leading to 
treatment failure [65]. Moreover, the mortality in patients 
with invasive infections due to bioﬁ  lm-producing 
Candida species has been reported signiﬁ  cantly higher 
[66]. Th   e activity of antifungals against bioﬁ  lm therefore 
has important clinical implications and is known to vary 
among diﬀ   erent agents. In particular, ﬂ  uconazole  and 
Figure 1. Proposed pre-emptive approach for management of candidemia in critically ill patients. ICU, intensive care unit; GI, 
gastrointestinal; TPN, total parenteral nutrition; CVC, central venous catheter.
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active against sessile forms, while echinocandins and 
amphotericin B oﬀ  er both bactericidal activity and good 
penetration into a bioﬁ  lm formed on vascular devices. 
However, a study performed on 43 Candida species – 
including 12 C.  albicans, 12 C. parapsilosis, 10 C. 
tropicalis and nine C. glabrata isolates – found that the 
activity of caspofungin and micafungin against a bioﬁ  lm 
of C. parapsilosis and C. tropicalis was signiﬁ  cantly lower 
than that of amphotericin B [67]. Table 5 outlines the 
susceptibility of diﬀ  erent  Candida species to two 
antifungals that are active against bioﬁ  lm-producing 
strains.
Antifungal agents
In recent years, numerous new antifungal drugs have 
been developed, studied and approved for various indica-
tions, and almost all of these new drugs are licensed to 
treat candidemia in diﬀ   erent patient populations. Th  e 
most appropriate antifungal drug can be chosen from the 
three main groups: the polyenes (amphotericin B deoxy-
cholate, lipid complex, liposomal); the azoles (ﬂ  ucona-
zole, voriconazole, posaconazole, itraconazole, ravucona-
zole); and the echinocandins (caspofungin, micafungin, 
anidulafungin).
Most of the studies on eﬃ   cacy in candidemia have not 
shown signiﬁ  cant  diﬀ   erences between various agents. 
Th  e diﬀ  erences in drug-related toxicity are signiﬁ  cant, 
however, and the possibility of drug–drug interactions – 
so important in critically ill patients that receive 
numerous medications – varies signiﬁ  cantly among the 
single agents. Th   e choice of the best antifungal therefore 
still poses a challenge for a clinician. Th  e detailed 
description of various agents used for treating 
candidemia is beyond the scope of the present review, 
but the dosing of the main antifungals is reported in 
Table 6. Moreover, given that echinocandins are the most 
recently introduced class of antifungals and general 
recommendations do not usually specify which of them 
should be used, Table 7 outlines the diﬀ  erences  in 
indication, dosing, and so forth, for three echinocandin 
compounds. Considering that many ICU patients have 
other signiﬁ   cant comorbidities, data on the treatment 
with various antifungals in the case of renal or hepatic 
insuﬃ   ciency are reported in Table 8.
Management of candidemia in the neonatal ICU
Th  e incidence of candidemia in the neonatal ICU has 
been increasing, mostly due to the fact that more low-
birth-weight and very-low-birth-weight newborns sur  vive 
longer thanks to advances in medical technology. Th  ese 
Table 5. Activity against diff  erent Candida species of two 
antifungals active against Candida biofi  lm-producing 
stains
Species Amphotericin  B  Echinocandins
Candida albicans S  S
Candida glabrata S  S
Candida krusei S  S
Candida lusitaniae  S to Ra  S
Candida parapsilosis  S  S to Rb
Candida tropicalis  S  S to Rb
S, susceptible; R, resistant. aResistance uncommon but can develop in initially 
susceptible species. bHigher minimum inhibitory concentration values and poor 
activity against biofi  lm for caspofungin and micafungin [67].
Figure 2. Relationship between diff  erent antifungal strategies, probability of invasive candidiasis and number of patients potentially 
treated.
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cations, and candidemia is one of the most frequent 
nosocomial bloodstream infections in this population. 
Th   e reported risk factors for candidemia in neonates and 
adults are similar, and include central venous catheters 
and arterial lines, parenteral nutrition, mechanical 
ventilation, and the extended use of antibiotics. Unlike in 
the adult ICU, C.  albicans  remains the most common 
isolate in the neonatal ICU – although non-albicans 
species such as C.  parapsilosis  and  C. tropicalis are 
increasingly common [68,69]. Fortu  nately, these species 
are susceptible to ﬂ  uconazole.
Th  e recent Infectious Diseases Society of America 
guidelines on management of Candida infections oﬀ  er 
recommendations for paediatric patients. In particular, 
the following treatments are regarded as ﬁ  rst-line therapy 
for neonatal candidiasis: amphotericin B deoxycholate, or 
liposomal amphotericin B if urinary tract involvement is 
excluded, and ﬂ  uconazole. Th   e guidelines also state that 
echinocandins should be used with caution and are 
Table 6. Dosing of currently available antifungals for treating candidemia
Drug  Loading dose (fi  rst 24 hours)  Daily dose
Fluconazole  800 mg (12 mg/kg)  400 mg (6 mg/kg)
Itraconazole –  200  mg/day*
Voriconazole  6 mg/kg every 12 hours for fi  rst two doses  3 mg/kg every 12 hours
Posaconazole  –  200 mg x 3*
Amphotericin B deoxycholate  –  0.5 to 1 mg/kg
Liposomal amphotericin B   –  3 mg/kg
Lipid complex amphotericin B  –  5 mg/kg
Anidulafungin  200 mg  100 mg
Caspofungin  70 mg  50 mg
Micafungin –  100  mg
*After a full meal.
Table 7. Main diff  erences between the three echinocandins available
Variable Anidulafungin  Caspofungin  Micafungin
Loading dose  200 mg  70 mg   None
  100 mg for EC  No loading dose for EC 
    
Daily dose for diff  erent indications  100 mg/day  50 mg/day  100 mg/day for candidemia
  50 mg/day for EC    150 mg/day for EC
      50 mg/day in prophylaxis
    
Age of patients according to FDA indication  Adults  >3 months  Neonates
     Children
     Adults
Metabolism  Slow chemical degradation at   Hepatic metabolism +   Hepatic metabolism + enzymatic
  physiologic temperature and pH  spontaneous chemical  biotransformation
   degradation
Indication for Aspergillus infection  None  Yes, in patients who are refractory   None
    to or intolerant of other therapies
Indications in neutropenic patients  None  Empirical therapy for presumed   Prophylaxis of Candida infections in
    fungal infections in febrile,   HSCT recipients
   neutropenic  patients 
Dose adjustment in moderate   None  Dose reduced (see Table 9)  None
hepatic impairment
Dose adjustment in severe hepatic   None  Unknown  Unknown
impairment
Data deriving from Food and Drug Administration (FDA) labels. EC, oesophageal candidiasis; HSCT, haematopoietic stem cell transplant.
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toxicity precludes the use of ﬂ  uconazole or amphotericin 
B. Dosing of antifungals in paediatric patients is outlined 
in Table 9.
Additionally for neonates, a lumbar puncture and a 
dilated retinal examination – preferably by an ophthal-
mologist – are recommended in those with sterile body 
ﬂ   uid and/or urine cultures positive for Candida,  and 
removal of the intravascular catheter is strongly recom-
mended. Finally, in nurseries with high rates of invasive 
candidiasis, ﬂ  uconazole prophylaxis may be considered 
in neonates with birth weight <1,000 g.
Conclusions
Candida is one of the most common causes of 
nosocomial bloodstream infection. Morbidity and 
mortality associated with candidemia are signiﬁ  cant and 
the epidemiology of species has been changing, at both 
local and worldwide levels. Even though numerous risk 
factors for invasive Candida infection have been reported 
and several antifungals are widely available, the optimal 
management of candidemia remains a challenge. Th  e 
agents recommended for initial treatment of candidemia 
in critically ill patients include echinocandins and lipid 
formulation of amphotericin B, but the choice between 
prophylactic, empirical and pre-emptive therapy is 
crucial. Compared with prophylaxis, empirical and pre-
emptive approaches allow the clinician to reduce expo-
sure to antifungals by targeting only patients at high risk 
of candidemia, without delaying therapy until yeast is 
identiﬁ  ed in blood cultures. A pre-emptive strategy is 
based on the presence of numerous risk factors, together 
with micro  biological documentation for the presence of 
Candida, such as multifocal colonisation or positive 
serum β-d-glucan. Further prospective studies are 
Table 8. Dose adjustment required in case of renal and hepatic impairment
Drug Dose  adjustment  Comments
Renal impairment   
 All  echinocandins  None  –
  Fluconazole  Yes  50% of the dose if CrCl <50
  Itraconazole oral solution  None  Do not use intravenous formulation due to carrier accumulation (cyclodextrin) if CrCl <30
  Posaconazole  None  If CrCl <20, monitor closely for breakthrough infections due to the variability in exposure
  Voriconazole, oral formulation only  None  Do not use intravenous formulation due to carrier accumulation (cyclodextrin) if CrCl <50
  Amphotericin B deoxycholate  Do not use  Switch to less nephrotoxic formulation 
  Amphotericin B lipid formulations  Unknown  –
Hepatic impairment   
 Anidulafungin  None 
  Caspofungin  Yes  Moderate hepatic impairment (Child–Pugh score 7 to 9) 35 mg daily, with 70 mg loading 
     dose 
  Micafungin  None  No data in severe hepatic impairment
 Fluconazole  None 
  Itraconazole oral solution  Unknown  Patients with impaired hepatic function should be carefully monitored when taking 
     itraconazole
 Posaconazole  None 
  Voriconazole   Yes  50% of maintenance dose in mild to moderate hepatic impairment (Child–Pugh class A and 
      B); no data in Child–Pugh class C; patients with hepatic insuffi   ciency must be carefully 
      monitored for drug toxicity
 Amphotericin  B  Unknown 
CrCl, creatinine clearance (ml/minute).
Table 9. Dosing of antifungals in paediatric patients
Drug Dose
Amphotericin B deoxycholate  1 mg/kg daily
Liposomal amphotericin B  3 mg/kg daily
Lipid complex amphotericin B  3 to 5 mg/kg daily (>1 month old)
Fluconazole  12 mg/kg daily
Caspofungin 50  mg/m2, with a loading dose of 
 70  mg/m2
 
(>1 year old)
Micafungin  2 mg/kg daily in children if <40 kg
Anidulafungin  1.5 mg/kg/day, with a loading dose 
  of 3 mg/kg/day (in children 2 to 
  17 years old)
Voriconazole  7 mg/kg every 12 hours, up to age 
 12  years
Data presented in order of strength in recommendation for invasive candidiasis.
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pre-emptive treatment of candidemia.
Abbreviations
ICU, intensive care unit; PCR, polymerase chain reaction.
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